Insys Therapeutics (INSY) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Cuts Price Target as Insys Therapeutics' (INSY) Guides to a Decline in Subsys Sales
February 24, 2016 10:20 AM ESTPiper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and cut the price target to $46.00 (from $49.00), following the company's 4Q earnings report. Insys reported adjusted diluted EPS of $0.36 on revenues of $91M, in-line with Street estimates. INSY is guiding to a sequential decline in Subsys sales in 1Q16, driven in significant part by the company no longer contracting with OptumRx. This is... More
